HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

nitrosocobalamin

devoid of relaxant activity in aortic rings, but causes a slowly developing & prolonged relaxation of anococcygeus muscles

Also Known As:

NO-Cbl

Networked: 9 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Bauer, Joseph A: 8 articles (12/2020 - 07/2002)
2.	Lindner, Daniel J: 5 articles (12/2020 - 07/2002)
3.	Lupica, Joseph A: 4 articles (12/2020 - 10/2003)
4.	Morrison, Bei H: 3 articles (12/2007 - 07/2002)
5.	Didonato, Joseph A: 2 articles (12/2020 - 12/2007)
6.	Sysel, Annette M: 2 articles (04/2014 - 09/2012)
7.	Tang, Zhuo: 2 articles (08/2006 - 10/2003)
8.	Dunphy, Michael J: 1 article (04/2014)
9.	Griffith, Kristie: 1 article (04/2014)
10.	Sherrod, Taylor: 1 article (04/2014)

Related Diseases

1.	Neoplasms (Cancer) 12/01/2020 - "NO-Cbl treatment rendered Apo2L/TRAIL-resistant malignancies sensitive to the anti-tumor effects of Apo2L/TRAIL in vitro and in vivo. " 12/01/2020 - "NO-Cbl and Apo2L/TRAIL exerted synergistic anti-tumor activity against A375 xenografts. " 10/01/2010 - "(1) The Giant Schnauzer demonstrated a 77% reduction in tumor volume after ten weeks of daily NO-Cbl treatment. " 10/10/2003 - "The use of NO-Cbl and Apo2L/TRAIL capitalizes on the tumor-specific properties of both agents and represents a promising anti-cancer combination." 10/10/2003 - "NO-Cbl treatment rendered Apo2L/TRAIL-resistant malignancies sensitive to the anti-tumor effects of Apo2L/TRAIL in vitro and in vivo. "
2.	Melanoma (Melanoma, Malignant) 10/10/2003 - "The specific aim of this study was to examine whether NO-Cbl could sensitize drug-resistant melanomas to Apo2L/TRAIL. " 12/01/2020 - "NO-Cbl sensitized Apo2L/TRAIL-resistant melanoma cell lines to growth inhibition by Apo2L/TRAIL, but had minimal effect on normal cell lines. " 12/01/2020 - "Athymic nude mice bearing human melanoma A375 xenografts were treated with NO-Cbl and Apo2L/TRAIL. " 12/01/2020 - "Antiproliferative effects of NO-Cbl and Apo2L/TRAIL were assessed in malignant melanomas and non-tumorigenic melanocyte and fibroblast cell lines. " 10/10/2003 - "NO-Cbl sensitized Apo2L/TRAIL-resistant melanoma cell lines to growth inhibition by Apo2L/TRAIL but had minimal effect on normal cell lines. "
3.	Ovarian Neoplasms (Ovarian Cancer) 07/03/2002 - "Xenograft tumors of human ovarian cancer NIH-OVCAR-3 cells were established in athymic nude mice, and tumor growth was monitored after treatment with NO-Cbl and IFN-beta, both individually and concomitantly. "
4.	Renal Cell Carcinoma (Grawitz Tumor) 08/01/2006 - "Human melanoma (A375), renal carcinoma (ACHN), and ovarian carcinoma (NIH-OVCAR-3) cells were treated with NO-Cbl and subjected to the biotin switch assay; S-nitrosylated DR4 was detected in all three cell lines. "
5.	Carcinoma (Carcinomatosis) 08/01/2006 - "Human melanoma (A375), renal carcinoma (ACHN), and ovarian carcinoma (NIH-OVCAR-3) cells were treated with NO-Cbl and subjected to the biotin switch assay; S-nitrosylated DR4 was detected in all three cell lines. "

Related Drugs and Biologics

1.	nitrosylcobalamin
2.	Vitamin B 12 (Cyanocobalamin)
3.	Nitric Oxide (Nitrogen Monoxide)
4.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
5.	Ligands
6.	Caspase 8 (Caspase-8)
7.	Caspase 3 (Caspase-3)
8.	Nitric Oxide Donors
9.	Vitamins
10.	Transcobalamins (Transcobalamin II)

Related Therapies and Procedures

1.	Therapeutics
2.	Aftercare (After-Treatment)